Amplitude Titration to Improve ECT Clinical Outcomes

Launched by UNIVERSITY OF NEW MEXICO · Jan 13, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how different settings for ECT (electroconvulsive therapy) might affect older adults with depression. Specifically, it is comparing two approaches: one where the strength of the electrical current is adjusted for each person (individualized amplitude) versus a fixed strength of 800 mA. Researchers want to see if the personalized approach leads to better results in reducing depression symptoms and if it has less impact on thinking abilities. The study will involve 50 participants who have been diagnosed with major depressive disorder or bipolar II and are recommended for ECT.

To take part in this trial, participants need to be between 18 and 262 years old and must meet certain health criteria, such as being diagnosed with specific types of depression and not having certain neurological disorders like Alzheimer's or epilepsy. During the trial, participants can expect to receive ECT treatment and be closely monitored for changes in their mood and cognitive functions. This study is currently recruiting participants, and everyone is welcome regardless of gender. If you or someone you know is struggling with depression and might be interested in this trial, it could be a good opportunity to explore new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of major depressive disorder or bipolar II
• • Clinical indications for ECT with right unilateral electrode placement
• Exclusion Criteria:
• • Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)
• • Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder)
• • Current drug or alcohol use disorder (except for nicotine)
• • Contraindications to MRI.